Top Clinical Trials companies in Denmark by Revenue

This ranking features the top 17 Clinical Trials companies in Denmark ranked by Revenue, totaling a Revenue of USD 48.31 B, for June 30, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Price to Earnings Ratio (P/E) EBIT EBITDA Net Income Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

Frequently Asked Questions

Which Clinical Trials company in Denmark has the highest Revenue ?

The Clinical Trials company in Denmark with the highest Revenue is Novo Nordisk A/S (Copenhagen Stock Exchange: NOVO-B.CO) at USD 40.19 B.
Which Clinical Trials company in Denmark has the lowest Revenue ?

The Clinical Trials company in Denmark with the lowest Revenue is 2cureX AB (publ) (Stockholm Stock Exchange: 2CUREX.ST) at None.

What are the top 10 Clinical Trials companies in Denmark by Revenue ?

The top 10 Clinical Trials companies in Denmark by Revenue are Novo Nordisk A/S, H. Lundbeck A/S, Genmab A/S, Bavarian Nordic A/S, ALK-Abelló A/S, Ascendis Pharma A/S, ChemoMetec A/S, Gubra A/S, Saniona AB (publ) and Zealand Pharma A/S.
What are the bottom 10 Clinical Trials companies in Denmark by Revenue ?

The bottom 10 Clinical Trials companies in Denmark by Revenue are 2cureX AB (publ), IO Biotech, Inc., Initiator Pharma A/S, FluoGuide A/S, ViroGates A/S, Danish Aerospace Company A/S, BioPorto A/S, Zealand Pharma A/S, Saniona AB (publ) and Gubra A/S.